AHR and cancer: In contrast to cancer cell lines, including HeLa, HepG2, and HEK293T cells, AhR expression was scarce in hiPSCs (Figure 3G) and neither its inhibition by siRNA or potent inhibitor StemRegenin-1 (SR-1) influence cell growth capability (Figures 3H, 3I, and S3C) nor did an increase in growth occur with the addition of a potent AhR ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (Figure S3D).